HOW WE ARE DIFFERENT
EquiFlow is a biologic intended to support a reduction in the risk of Exercise Induced Pulmonary Hemorrhage (EIPH- which is commonly referred to as simply “bleeding”) and mucous. It is administered by nebulizer so no needles!
WHAT IS EIPH?
A condition caused by the rupturing of capillaries in the respiratory tract during extreme exertion like racing.
Let ReCellerate with its team of scientific and regulatory experts assist you with making your proposed veterinary regenerative medicine product a reality. ReCellerate can be your partner from start to finish helping to take your idea from product concept to commercialization. Some of the product services provided by ReCellerate and its team of experts include:
Design and Development
Characterization
Study Protocol Drafting and Review
Bench Testing
Proof of Concept Validation
Safety and Efficacy Testing
Manufacturing and Product Scale-Up
Compliance with Current Good Manufacturing Practices (cGMPs)
Design and Establishment of an Appropriate Quality Assurance / Quality Control Program (QA/QC)
Drafting and Adoption of Standard Operating Procedures (SOPs)
Mock Facility Audits for Regulatory Compliance
Strategic Regulatory Advice and Assistance for both FDA Drug Approval and USDA Biologic Licensing
Review of Marketing and Promotional Materials
Assessing and Mitigating Potential Risk
“My mare, Halo, has COPD and is a bleeder. After treating her with ReCellerate’s EquiFlow, her coughing and bleeding has been greatly reduced and I’ve seen huge improvements in her everyday training and attitude. I can’t thank ReCellerate enough for restoring her lungs to a healthy condition.”
Read about
ReCellerate’s Proposal to the KY Equine Drug & Research Council
Kentucky Equine Council
“Equiflow has shown early indications of controlling exercise-induced pulmonary hemorrhage, the company claims.”
